147 related articles for article (PubMed ID: 15143070)
1. Maturation of human tripeptidyl-peptidase I in vitro.
Golabek AA; Wujek P; Walus M; Bieler S; Soto C; Wisniewski KE; Kida E
J Biol Chem; 2004 Jul; 279(30):31058-67. PubMed ID: 15143070
[TBL] [Abstract][Full Text] [Related]
2. Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I.
Golabek AA; Kida E; Walus M; Wujek P; Mehta P; Wisniewski KE
J Biol Chem; 2003 Feb; 278(9):7135-45. PubMed ID: 12488460
[TBL] [Abstract][Full Text] [Related]
3. Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo.
Golabek AA; Walus M; Wisniewski KE; Kida E
J Biol Chem; 2005 Mar; 280(9):7550-61. PubMed ID: 15582991
[TBL] [Abstract][Full Text] [Related]
4. N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I.
Wujek P; Kida E; Walus M; Wisniewski KE; Golabek AA
J Biol Chem; 2004 Mar; 279(13):12827-39. PubMed ID: 14702339
[TBL] [Abstract][Full Text] [Related]
5. The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH.
Lin L; Sohar I; Lackland H; Lobel P
J Biol Chem; 2001 Jan; 276(3):2249-55. PubMed ID: 11054422
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.
Guhaniyogi J; Sohar I; Das K; Stock AM; Lobel P
J Biol Chem; 2009 Feb; 284(6):3985-97. PubMed ID: 19038967
[TBL] [Abstract][Full Text] [Related]
7. Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I.
Walus M; Kida E; Wisniewski KE; Golabek AA
FEBS Lett; 2005 Feb; 579(6):1383-8. PubMed ID: 15733845
[TBL] [Abstract][Full Text] [Related]
8. Prosegment of tripeptidyl peptidase I is a potent, slow-binding inhibitor of its cognate enzyme.
Golabek AA; Dolzhanskaya N; Walus M; Wisniewski KE; Kida E
J Biol Chem; 2008 Jun; 283(24):16497-504. PubMed ID: 18411270
[TBL] [Abstract][Full Text] [Related]
9. Heterologous expression and site-directed mutagenesis studies on the activation mechanism and the roles of the basic residues in the prosegment of aspergillopepsinogen I.
Inoue H; Hayashi T; Huang XP; Lu JF; Athauda SB; Kong KH; Yamagata H; Udaka S; Takahashi K
Eur J Biochem; 1996 May; 237(3):719-25. PubMed ID: 8647118
[TBL] [Abstract][Full Text] [Related]
10. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis.
Ezaki J; Takeda-Ezaki M; Oda K; Kominami E
Biochem Biophys Res Commun; 2000 Feb; 268(3):904-8. PubMed ID: 10679303
[TBL] [Abstract][Full Text] [Related]
11. Exploring the active site of tripeptidyl-peptidase II through studies of pH dependence of reaction kinetics.
Eklund S; Lindås AC; Hamnevik E; Widersten M; Tomkinson B
Biochim Biophys Acta; 2012 Apr; 1824(4):561-70. PubMed ID: 22266401
[TBL] [Abstract][Full Text] [Related]
12. Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders.
Wisniewski KE; Kida E; Walus M; Wujek P; Kaczmarski W; Golabek AA
Eur J Paediatr Neurol; 2001; 5 Suppl A():73-9. PubMed ID: 11589013
[TBL] [Abstract][Full Text] [Related]
13. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis.
Lin L; Lobel P
Biochem J; 2001 Jul; 357(Pt 1):49-55. PubMed ID: 11415435
[TBL] [Abstract][Full Text] [Related]
14. Tripeptidyl-peptidase I in health and disease.
Golabek AA; Kida E
Biol Chem; 2006 Aug; 387(8):1091-9. PubMed ID: 16895480
[TBL] [Abstract][Full Text] [Related]
15. Rat tripeptidyl peptidase I: molecular cloning, functional expression, tissue localization and enzymatic characterization.
Du PG; Kato S; Li YH; Maeda T; Yamane T; Yamamoto S; Fujiwara M; Yamamoto Y; Nishi K; Ohkubo I
Biol Chem; 2001 Dec; 382(12):1715-25. PubMed ID: 11843185
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the endopeptidase activity of tripeptidyl-peptidase II.
Eklund S; Dogan J; Jemth P; Kalbacher H; Tomkinson B
Biochem Biophys Res Commun; 2012 Aug; 424(3):503-7. PubMed ID: 22771804
[TBL] [Abstract][Full Text] [Related]
17. Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2).
Oyama H; Fujisawa T; Suzuki T; Dunn BM; Wlodawer A; Oda K
J Biochem; 2005 Aug; 138(2):127-34. PubMed ID: 16091586
[TBL] [Abstract][Full Text] [Related]
18. [Tripeptidyl-peptidase I--distribution, biogenesis, and mechanisms of activation].
Gołabek AA
Postepy Biochem; 2006; 52(1):16-23. PubMed ID: 16869297
[TBL] [Abstract][Full Text] [Related]
19. The conversion of recombinant human mast cell prochymase to enzymatically active chymase by dipeptidyl peptidase I is inhibited by heparin and histamine.
McEuen AR; Ashworth DM; Walls AF
Eur J Biochem; 1998 Apr; 253(1):300-8. PubMed ID: 9578489
[TBL] [Abstract][Full Text] [Related]
20. Purification and characterization of a tripeptidyl peptidase I from human osteoclastomas: evidence for its role in bone resorption.
Page AE; Fuller K; Chambers TJ; Warburton MJ
Arch Biochem Biophys; 1993 Nov; 306(2):354-9. PubMed ID: 8215436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
